Drug Pipeline

DNX-2401 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
2
Recruiting
2
Top Sponsors
4
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-28 NCT07424092
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors		 overall status: "Active Not Recruiting" → "Recruiting"
2026-05-16 NCT07424092
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors		 overall status: "Not Yet Recruiting" → "Active Not Recruiting"
2026-05-16 NCT07424092
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors		 date change Primary completion pushed: 2029-04 -> 2029-05
2026-05-16 NCT07424092
Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors		 date change Completion pushed: 2029-04 -> 2029-05
Active Studies by Phase
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT07424092 Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors High Grade Glioma Recruiting
Phase 1
NCT03896568 MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma IDH1 wt Allele Recruiting
NCT07444606 Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for… Melanoma Not Yet Recruiting
Sponsors Running DNX-2401 Trials
M.D. Anderson Cancer Center (2) Clinica Universidad de Navarra, Universidad de Navarra (1)
Disease Areas
Glioma (2) Glioblastoma (1) Sarcoma (1) Melanoma (1)
Get alerts when DNX-2401 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free